TY - JOUR
T1 - International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
AU - Kumar, Shaji
AU - Paiva, Bruno
AU - Anderson, Kenneth C.
AU - Durie, Brian
AU - Landgren, Ola
AU - Moreau, Philippe
AU - Munshi, Nikhil
AU - Lonial, Sagar
AU - Bladé, Joan
AU - Mateos, Maria Victoria
AU - Dimopoulos, Meletios
AU - Kastritis, Efstathios
AU - Boccadoro, Mario
AU - Orlowski, Robert
AU - Goldschmidt, Hartmut
AU - Spencer, Andrew
AU - Hou, Jian
AU - Chng, Wee Joo
AU - Usmani, Saad Z.
AU - Zamagni, Elena
AU - Shimizu, Kazuyuki
AU - Jagannath, Sundar
AU - Johnsen, Hans E.
AU - Terpos, Evangelos
AU - Reiman, Anthony
AU - Kyle, Robert A.
AU - Sonneveld, Pieter
AU - Richardson, Paul G.
AU - McCarthy, Philip
AU - Ludwig, Heinz
AU - Chen, Wenming
AU - Cavo, Michele
AU - Harousseau, Jean Luc
AU - Lentzsch, Suzanne
AU - Hillengass, Jens
AU - Palumbo, Antonio
AU - Orfao, Alberto
AU - Rajkumar, S. Vincent
AU - Miguel, Jesus San
AU - Avet-Loiseau, Herve
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.
AB - Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.
UR - http://www.scopus.com/inward/record.url?scp=84995917601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995917601&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(16)30206-6
DO - 10.1016/S1470-2045(16)30206-6
M3 - Review article
C2 - 27511158
AN - SCOPUS:84995917601
SN - 1470-2045
VL - 17
SP - e328-e346
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 8
ER -